Header Logo

Connection

RENE GONZALEZ to Skin Neoplasms

Back to Details
This is a "connection" page, showing publications RENE GONZALEZ has written about Skin Neoplasms.
RENE GONZALEZ
Connection Strength
5.265
Skin Neoplasms
  1. Advances in the treatment of Basal cell carcinoma: Hedgehog inhibitors. Semin Oncol. 2012 Apr; 39(2):139-44.
    View in: PubMed
    Score: 0.229
  2. Novel therapies in melanoma. Immunotherapy. 2011 Dec; 3(12):1461-9.
    View in: PubMed
    Score: 0.224
  3. A phase 2 study of high-dose Allovectin-7 in patients with advanced metastatic melanoma. Melanoma Res. 2010 Jun; 20(3):218-26.
    View in: PubMed
    Score: 0.202
  4. A phase 2 clinical trial of nab-paclitaxel in previously treated and chemotherapy-naive patients with metastatic melanoma. Cancer. 2010 Jan 01; 116(1):155-63.
    View in: PubMed
    Score: 0.196
  5. A multi-center phase II evaluation of the small molecule survivin suppressor YM155 in patients with unresectable stage III or IV melanoma. Invest New Drugs. 2011 Feb; 29(1):161-6.
    View in: PubMed
    Score: 0.193
  6. Development of vitiligo during melanoma treatment with a novel survivin inhibitor: a case report and review of the literature. Int J Dermatol. 2009 Apr; 48(4):426-30.
    View in: PubMed
    Score: 0.186
  7. Immunosuppressive dendritic and regulatory T cells are upregulated in melanoma patients. Ann Surg Oncol. 2007 Oct; 14(10):2854-60.
    View in: PubMed
    Score: 0.165
  8. Phase 2 trial of Allovectin-7 in advanced metastatic melanoma. Melanoma Res. 2006 Dec; 16(6):521-6.
    View in: PubMed
    Score: 0.158
  9. Metastatic melanoma in the breast: a report of 27 cases. J Surg Oncol. 2006 Aug 01; 94(2):101-4.
    View in: PubMed
    Score: 0.155
  10. Phase II multicenter study of neoadjuvant biochemotherapy for patients with stage III malignant melanoma. J Clin Oncol. 2006 Jul 01; 24(19):3157-63.
    View in: PubMed
    Score: 0.154
  11. Expanding the landscape of oncogenic drivers and treatment options in acral and mucosal melanomas by targeted genomic profiling. Int J Cancer. 2024 Nov 15; 155(10):1792-1807.
    View in: PubMed
    Score: 0.134
  12. A phase II study of neoadjuvant biochemotherapy for stage III melanoma. Cancer. 2002 Jan 15; 94(2):470-6.
    View in: PubMed
    Score: 0.113
  13. Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone Versus Ipilimumab in Patients With Advanced Melanoma. J Clin Oncol. 2022 01 10; 40(2):127-137.
    View in: PubMed
    Score: 0.112
  14. Whole-genome sequencing of acral melanoma reveals genomic complexity and diversity. Nat Commun. 2020 10 16; 11(1):5259.
    View in: PubMed
    Score: 0.104
  15. Pembrolizumab Monotherapy for Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma: A Single-Arm Phase II Trial (KEYNOTE-629). J Clin Oncol. 2020 09 01; 38(25):2916-2925.
    View in: PubMed
    Score: 0.102
  16. Extended 5-Year Follow-up Results of a Phase Ib Study (BRIM7) of Vemurafenib and Cobimetinib in BRAF-Mutant Melanoma. Clin Cancer Res. 2020 01 01; 26(1):46-53.
    View in: PubMed
    Score: 0.097
  17. A nomogram to predict node positivity in patients with thin melanomas helps inform shared patient decision making. J Surg Oncol. 2019 Dec; 120(7):1276-1283.
    View in: PubMed
    Score: 0.097
  18. Inflammatory side effects of BRAF and MEK inhibitors. Melanoma Res. 2019 10; 29(5):522-526.
    View in: PubMed
    Score: 0.096
  19. Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma. N Engl J Med. 2019 10 17; 381(16):1535-1546.
    View in: PubMed
    Score: 0.096
  20. Atezolizumab plus cobimetinib and vemurafenib in BRAF-mutated melanoma patients. Nat Med. 2019 06; 25(6):929-935.
    View in: PubMed
    Score: 0.094
  21. Evaluation of Two Dosing Regimens for Nivolumab in Combination With Ipilimumab in Patients With Advanced Melanoma: Results From the Phase IIIb/IV CheckMate 511 Trial. J Clin Oncol. 2019 04 10; 37(11):867-875.
    View in: PubMed
    Score: 0.092
  22. Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial. Lancet Oncol. 2018 11; 19(11):1480-1492.
    View in: PubMed
    Score: 0.090
  23. Final analysis of a randomised trial comparing pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory advanced melanoma. Eur J Cancer. 2017 11; 86:37-45.
    View in: PubMed
    Score: 0.084
  24. Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma. N Engl J Med. 2017 10 05; 377(14):1345-1356.
    View in: PubMed
    Score: 0.084
  25. Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma. N Engl J Med. 2017 11 09; 377(19):1824-1835.
    View in: PubMed
    Score: 0.084
  26. Efficacy and Safety Outcomes in Patients With Advanced Melanoma Who Discontinued Treatment With Nivolumab and Ipilimumab Because of Adverse Events: A Pooled Analysis of Randomized Phase II and III Trials. J Clin Oncol. 2017 Dec 01; 35(34):3807-3814.
    View in: PubMed
    Score: 0.083
  27. Association of sentinel lymph node diameter with melanoma metastasis. Am J Surg. 2016 Aug; 212(2):315-20.
    View in: PubMed
    Score: 0.074
  28. Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial. Lancet Oncol. 2015 Aug; 16(8):908-18.
    View in: PubMed
    Score: 0.072
  29. Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. N Engl J Med. 2015 Jul 02; 373(1):23-34.
    View in: PubMed
    Score: 0.071
  30. Phase II Study of Nilotinib in Melanoma Harboring KIT Alterations Following Progression to Prior KIT Inhibition. Clin Cancer Res. 2015 May 15; 21(10):2289-96.
    View in: PubMed
    Score: 0.070
  31. A review of novel therapies for melanoma. Am J Clin Dermatol. 2014 Aug; 15(4):323-37.
    View in: PubMed
    Score: 0.067
  32. Combination of vemurafenib and cobimetinib in patients with advanced BRAF(V600)-mutated melanoma: a phase 1b study. Lancet Oncol. 2014 Aug; 15(9):954-65.
    View in: PubMed
    Score: 0.067
  33. A single-arm, open-label, expanded access study of vemurafenib in patients with metastatic melanoma in the United States. Cancer J. 2014 Jan-Feb; 20(1):18-24.
    View in: PubMed
    Score: 0.065
  34. New targeted therapies in melanoma. Cancer Control. 2013 Oct; 20(4):282-8.
    View in: PubMed
    Score: 0.064
  35. Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin. J Clin Oncol. 2013 Sep 10; 31(26):3182-90.
    View in: PubMed
    Score: 0.062
  36. Long-term follow-up and survival of patients following a recurrence of melanoma after a negative sentinel lymph node biopsy result. JAMA Surg. 2013 May; 148(5):456-61.
    View in: PubMed
    Score: 0.062
  37. Pharmacodynamic effects and mechanisms of resistance to vemurafenib in patients with metastatic melanoma. J Clin Oncol. 2013 May 10; 31(14):1767-74.
    View in: PubMed
    Score: 0.061
  38. Phase II study of the MEK1/MEK2 inhibitor Trametinib in patients with metastatic BRAF-mutant cutaneous melanoma previously treated with or without a BRAF inhibitor. J Clin Oncol. 2013 Feb 01; 31(4):482-9.
    View in: PubMed
    Score: 0.060
  39. Safety profile and pharmacokinetic analyses of the anti-CTLA4 antibody tremelimumab administered as a one hour infusion. J Transl Med. 2012 Nov 21; 10:236.
    View in: PubMed
    Score: 0.060
  40. Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial. Lancet Oncol. 2012 Aug; 13(8):782-9.
    View in: PubMed
    Score: 0.058
  41. A neoadjuvant biochemotherapy approach to stage III melanoma: analysis of surgical outcomes. Immunotherapy. 2012 Jul; 4(7):679-86.
    View in: PubMed
    Score: 0.058
  42. Side population cells from human melanoma tumors reveal diverse mechanisms for chemoresistance. J Invest Dermatol. 2012 Oct; 132(10):2440-2450.
    View in: PubMed
    Score: 0.058
  43. RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors. N Engl J Med. 2012 Jan 19; 366(3):207-15.
    View in: PubMed
    Score: 0.057
  44. gp100 peptide vaccine and interleukin-2 in patients with advanced melanoma. N Engl J Med. 2011 Jun 02; 364(22):2119-27.
    View in: PubMed
    Score: 0.054
  45. A phase 2 study of tasisulam sodium (LY573636 sodium) as second-line treatment for patients with unresectable or metastatic melanoma. Cancer. 2011 Oct 15; 117(20):4732-9.
    View in: PubMed
    Score: 0.053
  46. Immunologic therapy targeting metastatic melanoma: allovectin-7. Immunotherapy. 2011 Jan; 3(1):17-21.
    View in: PubMed
    Score: 0.053
  47. Serial monitoring of circulating tumor cells predicts outcome of induction biochemotherapy plus maintenance biotherapy for metastatic melanoma. Clin Cancer Res. 2010 Apr 15; 16(8):2402-8.
    View in: PubMed
    Score: 0.050
  48. A randomized phase 2 study of etaracizumab, a monoclonal antibody against integrin alpha(v)beta(3), + or - dacarbazine in patients with stage IV metastatic melanoma. Cancer. 2010 Mar 15; 116(6):1526-34.
    View in: PubMed
    Score: 0.050
  49. Phase II multicenter trial of maintenance biotherapy after induction concurrent Biochemotherapy for patients with metastatic melanoma. J Clin Oncol. 2009 Dec 20; 27(36):6207-12.
    View in: PubMed
    Score: 0.049
  50. Phase II clinical trial of a granulocyte-macrophage colony-stimulating factor-encoding, second-generation oncolytic herpesvirus in patients with unresectable metastatic melanoma. J Clin Oncol. 2009 Dec 01; 27(34):5763-71.
    View in: PubMed
    Score: 0.048
  51. A case of Merkel cell carcinoma. Oncology (Williston Park). 2008 Mar; 22(3):322-8.
    View in: PubMed
    Score: 0.043
  52. Size of sentinel node metastases predicts other nodal disease and survival in malignant melanoma. Am J Surg. 2006 Dec; 192(6):878-81.
    View in: PubMed
    Score: 0.040
  53. Serial monitoring of circulating melanoma cells during neoadjuvant biochemotherapy for stage III melanoma: outcome prediction in a multicenter trial. J Clin Oncol. 2005 Nov 01; 23(31):8057-64.
    View in: PubMed
    Score: 0.037
  54. Survival in sentinel lymph node-positive pediatric melanoma. J Pediatr Surg. 2005 Jun; 40(6):988-92; discussion 992.
    View in: PubMed
    Score: 0.036
  55. Identifying risk factors for complications following sentinel lymph node biopsy for melanoma. Arch Surg. 2005 Jan; 140(1):85-9.
    View in: PubMed
    Score: 0.035
  56. Sentinel lymph node biopsy for melanoma and other melanocytic tumors in adolescents. J Pediatr Surg. 2005 Jan; 40(1):232-5.
    View in: PubMed
    Score: 0.035
  57. A phase II study of biochemotherapy for advanced melanoma incorporating temozolomide, decrescendo interleukin-2 and GM-CSF. Cancer Invest. 2005; 23(4):303-8.
    View in: PubMed
    Score: 0.035
  58. A young woman with melanoma diagnosed during pregnancy. Oncology (Williston Park). 2004 Jun; 18(7):794-9.
    View in: PubMed
    Score: 0.033
  59. Results from a randomized phase III study comparing combined treatment with histamine dihydrochloride plus interleukin-2 versus interleukin-2 alone in patients with metastatic melanoma. J Clin Oncol. 2002 Jan 01; 20(1):125-33.
    View in: PubMed
    Score: 0.028
  60. Gene expression profiling for molecular staging of cutaneous melanoma in patients undergoing sentinel lymph node biopsy. J Am Acad Dermatol. 2015 May; 72(5):780-5.e3.
    View in: PubMed
    Score: 0.018
  61. Development of a prognostic genetic signature to predict the metastatic risk associated with cutaneous melanoma. Clin Cancer Res. 2015 Jan 01; 21(1):175-83.
    View in: PubMed
    Score: 0.017
  62. The Society for Immunotherapy of Cancer consensus statement on tumour immunotherapy for the treatment of cutaneous melanoma. Nat Rev Clin Oncol. 2013 10; 10(10):588-98.
    View in: PubMed
    Score: 0.016
  63. A phase 1-2 study of imexon plus dacarbazine in patients with unresectable metastatic melanoma. Cancer. 2010 Aug 01; 116(15):3683-91.
    View in: PubMed
    Score: 0.013
  64. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010 Aug 19; 363(8):711-23.
    View in: PubMed
    Score: 0.013
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.